To investigate whether TSG-6, detected in MSC-CM EXO 25 wks, acts as one of the mediators in attenuation of BPD pathology, we injected recombinant human (rh) TSG-6 intraperitoneally in the BPD mouse model and studied its therapeutic effects. Here, TNFAIP6 is linked to bronchopulmonary dysplasia.